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Abstract
We report a woman aged 37 years who showed rapid deterioration of psy-
chomotor functions 6 months after a subtotal thyroidectomy for Graves’ 
thyrotoxicosis. In addition to cobalamin deficiency, we observed pathologic 
changes in the brain tissue in accordance with a white matter disorder on 
brain imaging. The neurologic deficits and leukoencephalopathic changes 
in brain imaging responded to cobalamin replacement and returned to nor-
mal 6 months after treatment. The relationship between thyroid dysfunc-
tion and cobalamin levels in maintaining white matter is briefly reviewed. 
[Tzu Chi Med J 2009;21(1):85–88]
Article info
Article history:
Received: January 31, 2008
Revised: March 3, 2008
Accepted: June 2, 2008
Keywords:
Cobalamin
Leukoencephalopathy
Thyroid
White matter
*Corresponding author. Department of Neurology, Buddhist Tzu Chi General Hospital, 707, 
Section 3, Chung-Yang Road, Hualien, Taiwan.
E-mail address: wenlong1109@hotmail.com
1. Introduction
Cobalamin (vitamin B12) and thyroid hormone play 
significant roles in regulating central metabolic path-
ways [1,2]. The integrity of nerve myelin requires ad-
equate levels of cobalamin as a cofactor for myelin 
phospholipid methylation, closely related to the serum 
levels of homocysteine and methylmalonic acid. More-
over, thyroid hormone plays a fundamental role in 
regulating oligodendrocyte development [2]. Hyper-
thyroidism has been associated with increased oxida-
tive stress [3] and necrotic neuron death [4]. In unique 
conditions, overt thyroid function may influence homo-
cysteine levels and cobalamin function [5]. Here, we 
report the case of a woman aged 37 years who devel-
oped symptoms of thyrotoxicosis and then 6 months 
after her thyroidectomy, developed white matter dis-
ease. Her blood cobalamin level was exceptionally 
low. Cobalamin replacement improved the impaired 
neurobehavioral function of the patient.
2. Case report
A non-vegetarian housewife aged 37 years was admit-
ted with subacute onset of progressive deterioration 
of ambulatory, linguistic and cognitive functions occur-
ring over a period of 1 month. Her history revealed 
no cognitive dysfunction, mental illness, hypertension, 
stroke, migraine, uremia, central nervous system in-
fection or familial hereditary leukodystrophy, and she 
had no history of substance abuse. There was also 
no history of intake of vitamin supplements. She had 
been continually medicated with famotidine (one tab-
let 20 mg twice daily) for erosive gastritis and a duo-
denal ulcer for about 2 years. She had been diagnosed 
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with Graves’ disease 2 years previously and had poor 
methimazole and propylthiouracil medical compliance. 
Six months prior to the development of neurologic 
dysfunction, she received a subtotal thyroidectomy 
for poorly controlled Graves’ thyrotoxicosis. At that 
time, her blood levels were: T3 > 600 ng/dL (reference 
range, 80–220 pg/mL), T4 > 24 ng/dL (reference range, 
4.5–12.5 ng/mL), and thyroid-stimulating hormone 
0.007 μIU/mL (reference range, 0.4–4.0 μIU/mL). After 
surgery, the patient had shown transient hypothyroidism 
(T3, 62.3 ng/dL; T4, 4.63 μg/dL; TSH, 6.60 μIU/mL) for 
3 months. She did not receive thyroxine supplemen-
tation for her hypothyroidism.
On admission, the patient was wheelchair-bound, 
could open her eyes spontaneously, and was inatten-
tive, unresponsive to verbal stimuli and unaware of 
micturition and defecation. Her pupils were 3 mm in 
diameter and reactive, and the fundi were normal. Eye 
movements were conjugate. Corneal reflexes were 
present bilaterally. The face was symmetrical. All four 
limbs withdrew from noxious stimulation and she had 
normal tendon reflexes. No Babinski’s or Hoffmann’s 
signs were demonstrated. It was difficult to evaluate 
proprioceptive sensory tests for depressed mental 
status. Her complete blood count (hemoglobin, 12 g/dL; 
hematocrit, 37%; mean corpuscular volume, 88.1 fL), 
urine toxicology and drug abuse screen were unre-
markable, and rapid plasma regain, human immu-
nodeficiency virus, antinuclear antibodies, Sjögren 
antibodies and metabolic screening including BUN/
creatinine, glucose, electrolytes, and liver function 
were all within normal limits. With the exception of 
a low cobalamin level (176 pg/mL [reference range, 
193–982 pg/mL]), no other biochemical or serological 
abnormalities or infectious indicators were detected. 
Electroencephalography showed a mix of diffuse theta 
and slow alpha frequencies. The results obtained from 
cerebrospinal fluid analysis showed no abnormalities 
on cytology, staining, and bacterial and tuberculosis 
cultures. Antibodies to parietal cells were not observed. 
T2 fluid-attenuated inversion recovery brain mag-
netic resonance imaging (MRI) revealed high signal 
intensity in the bilateral fronto-temporal-parietal sub-
cortical regions and in the corpus callosum (Fig. 1). 
No apparent abnormality was observed in the spine 
on MRI. The unusual confluent white matter abnor-
malities on MRI were confirmed by a stereotactic brain 
biopsy. The sampled tissue showed multifocal demy-
elination and vacuolization (Fig. 2).
The patient was treated with hydroxocobalamin, 
1 mg intramuscular injection daily for 10 days. After 
3 weeks of hospitalization, the patient could respond 
slowly to speech with simple words and walk with 
assistance. At this time, her Mini-Mental State Exami-
nation score was 15/30, with poor performance mainly 
in time orientation, language, attention and calcula-
tion. She was discharged to home care and received 
outpatient rehabilitation. One month later, the patient 
appeared to be more alert on her outpatient visit. Five 
months later, she had recovered and was assessed 
as being in a normal neurobehavioral state. The white 
matter abnormalities appeared almost undetectable 
on MRI scans performed at the 6-month follow-up 
(Fig. 3). At this time, her thyroid function and cobala-
min levels were within the normal ranges.
3. Discussion
Cobalamin deficiency undoubtedly resulted in altera-
tion of cognition in this patient, but coexistence of 
thyroid dysfunction could also have contributed to the 
Fig. 1 — T2 fluid-attenuated inversion recovery brain magnetic resonance imaging shows bilateral white matter changes.
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leukoencephalopathy. The patient experienced tran-
sient hypothyroidism following a subtotal thyroidectomy 
and administration of propylthiouracil. The subsequent 
development of cognitive disorders was treated suc-
cessfully by discontinuing propylthiouracil and admin-
istering hydroxocobalamin.
Patients with uremia [6], eclampsia [7], malignant 
hypertension [8], collagen vascular disorders [9], throm-
botic thrombocytopenic purpura [10] and amyloid-
osis [11], or those receiving immunosuppressants are 
at risk of developing reversible leukoencephalopathy. 
These diseases and pharmaceutical agents are capa-
ble of disrupting the integrity of white matter, in turn 
influencing psychomotor processing speed. Patients 
present with attention deficits, executive dysfunction, 
memory-retrieval deficits, visuospatial impairment, 
and linguistic dysfunction. Analysis of the cobalamin 
level is routinely performed in patients presenting 
with dementia, but imaging or pathology studies of the 
human brain are rarely reported. Chatterjee et al [12] 
were the first to demonstrate brain pathology in a 
patient with cobalamin deficiency. The white matter 
vacuolization with gliosis and myelin sheath swelling 
described by Chatterjee et al were consistent with the 
microscopic findings of the sampled brain tissue from 
our patient.
The pathogenesis of the diffuse myelin and axonal 
abnormalities associated with cobalamin deficiency 
and thyroid dysfunction is not well understood. How-
ever, it is well documented that cobalamin and thyroid 
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Fig. 2 — Brain biopsy with hematoxylin and eosin staining reveals diffuse white matter vacuolization with gliosis and 
myelin sheath swelling: (A) 100´; (B) 200´.
Fig. 3 — At the 6-month follow-up, T2 fluid-attenuated inversion recovery brain magnetic resonance imaging shows 
partial resolution of white matter changes after 10 doses of hydroxocobalamin (1 mg intramuscular injection).
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hormone are required for normal axonal myelination 
[2]. Cobalamin as a cofactor participates in two enzy-
matic reactions in humans. First, it is a cofactor for the 
conversion of homocysteine to methionine, an essen-
tial requirement for DNA synthesis and maintenance 
of the myelin sheath by methylation. Second, it is nec-
essary for the conversion of methylmalonyl-CoA to 
succinyl-CoA. In states of cobalamin deficiency, ho-
mocysteine and methylmalonic acid levels rise in the 
blood. In addition, elevated methylmalonic acid may 
competitively inhibit succinate dehydrogenase (an 
enzyme essential for mitochondrial aerobic glucose 
oxidation) causing mitochondrial dysfunction, or may 
be incorporated abnormally into branched-chain fatty 
acids, resulting in abnormal myelination [13]. Colleran 
et al [5] reported that vitamin B and folate deficien-
cies, in association with thyrotoxicosis, may be risk 
factors for hyperhomocysteinemia and subsequent 
thromboembolic events. However, the serum cobala-
min level did not differ in a hyperthyroid or hypothy-
roid state [14]. Thyrotoxicosis may be associated with 
hyperhomocysteinuria and functional cobalamin de-
ficiency [3]. In addition, methylenetetrahydrofolate 
reductase expression is decreased in hypothyroidism 
[15], and therefore may result in decreasing remeth-
ylation and renal excretion of homocysteine. The ab-
normal myelination and elevated homocysteine cause 
atherosclerotic effects [16], inadequate cerebral per-
fusion, necrotic neuron damage and mitochondrial 
dysfunction, which may contribute to white matter 
change. The timeline of hyperthyroidism, subsequent 
hypothyroidism and altered cobalamin levels may cor-
relate with the appearance of neurologic disturbances. 
However, despite the abnormal cobalamin level iden-
tified in our patient, no noticeable abnormalities were 
observed following endoscopy and colonoscopy stud-
ies, and no antiparietal cell antibodies were detected. 
We acknowledge some limitations in our case report. 
We could not perform a Schilling test to demonstrate 
the underlying cause of cobalamin deficiency. In ad-
dition, we did not measure homocysteine and meth-
ylmalonic acid before cobalamin replacement, which 
would have better clarified their interrelationship.
Cobalamin deficiency is not uncommon in elderly 
people with gastric problems, in patients with long-
term use of proton pump inhibitors, or in individuals 
observing a strict vegetarian diet without vitamin 
supplementation. There is about a 12-month window 
of opportunity for cognitive recovery with cobalamin 
replacement [17]. Clinicians should consider subtle 
cobalamin deficiency and thyroid functional states 
when evaluating a wide range of cognitive and neuro-
psychiatric symptoms for early detection and treatment 
of patients with leukoencephalopathy [12]. Further 
study of the interaction between thyroid function, co-
balamin, folate, methylenetetrahydrofolate reductase, 
methylmalonic acid and homocysteine with cognitive 
function and white matter change is warranted to better 
understand the central metabolic pathways.
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